Standard BioTools Inc
LAB
Company Profile
Business description
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.
Contact
2 Tower Place
Suite 2000
South San FranciscoCA94080
USAT: +1 650 266-6000
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2025
Employees
539
Stocks News & Analysis
video
Do you qualify as 'rich'?
Morningstar's Sim Mody speaks with Mark LaMonica about the varying definitions of rich.
stocks
Megatrend Investing 2025 and beyond: ASX players to capitalise on the clean energy transition
Find out how you can benefit from global megatrends.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,628.40 | 161.30 | -1.84% |
| CAC 40 | 7,854.92 | 95.25 | -1.20% |
| DAX 40 | 21,428.24 | 303.81 | -1.40% |
| Dow JONES (US) | 44,421.91 | 122.75 | -0.28% |
| FTSE 100 | 8,583.56 | 90.40 | -1.04% |
| HKSE | 20,217.26 | 7.85 | -0.04% |
| NASDAQ | 19,391.96 | 235.49 | -1.20% |
| Nikkei 225 | 38,520.09 | 1,052.40 | -2.66% |
| NZX 50 Index | 12,840.79 | 30.47 | 0.24% |
| S&P 500 | 5,994.57 | 45.96 | -0.76% |
| S&P/ASX 200 | 8,379.40 | 152.90 | -1.79% |
| SSE Composite Index | 3,250.60 | 2.03 | -0.06% |